Dyax CorpNASDAQ:DYAX
Symbol Lookup
Refresh
Recent News»
0 New Today| Company | Market Cap | P/E Ratio (TTM) | EPS Growth (5yr) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fluidigm Corp FLDM | 421.0M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Furiex Pharmaceuticals Inc FURX | 373.5M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Enanta Pharmaceuticals Inc ENTA | 315.7M | 6.3x | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunomedics Inc IMMU | 355.7M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| XOMA Corp XOMA | 318.3M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Data delayed 15 minutes. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company Information
Dyax Corp. (Dyax), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. The principal focus of Dyax is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema. It developed KALBITOR (ecallantide) on its own in the United States for the treatment of acute attacks of HAE. Outside of the United States, it has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and it is evaluating opportunities in others. It leverages its phage display technology through the Licensing and Funded Research Program (LFRP).
| Headquarters | 55 Network Drive BURLINGTON, MA, United States 01803 |
|---|---|
| Phone | 617-225-2500 |
| Fax | 617-225-2501 |
EXECUTIVE OFFICERS
| Chairman of the Board | Henry Blair |
|---|---|
| President, Chief Executive Officer, Director | Gustav Christensen |
| Chief Financial Officer, Executive Vice President | George Migausky |
| Chief Medical Officer, Executive Vice President - Research and Development | Burt Adelman |
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
Open a New Account, or Login if you're a client.
(GAAP)*
| Market Cap | $352.7M | Beta | 1.58 |
|---|---|---|---|
| Revenue (TTM) | $55.2M | EPS | $-0.29 |
| Shares Out. | 109.2M | Book Value | $-0.52 |
| Dividend Yield | 0.00% | P/E | -- |
| Annual Dividend Rate | $0.00 | Price/Sales (TTM) | 6.4 |
| Ex-Div Date | 1/1/01 | P/Cash Flow (TTM) | -- |
| Pay Date | 1/1/01 | Operating Margin | -33.70% |
*GAAP = prior to non-GAAP analyst adjusted earnings.
(Non-GAAP)*
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
